# Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

> **NCT02527200** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 56 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Obesity

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02527200
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-09
- **Primary completion:** 2020-11-04
- **Final completion:** 2020-11-19
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02527200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02527200, "Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02527200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*